Will some pent-up deal pres­sure amp up a biotech ral­ly?

Over the last 6 weeks we’ve seen the Nas­daq biotech in­dex surge 21%, an ear­ly-stage com­pa­ny just up­sized its IPO and stuck to the range, sec­ondary of­fer­ings are do­ing bet­ter and a whole slate of big biotechs and phar­mas have made it plain that they’re hunt­ing for sig­nif­i­cant new deals be­fore the end of this year.

It’s the kind of en­vi­ron­ment that has peren­ni­al en­thu­si­asts cheer­ing a ral­ly that the in­dus­try hopes has legs need­ed to con­tin­ue past the dog days of sum­mer. And it has some big im­pli­ca­tions for the deal teams bar­ter­ing over biotech as­sets.

While Medi­va­tion $MD­VN is def­i­nite­ly in play, ru­mors abound that big out­fits like As­traZeneca $AZN and Bio­gen $BI­IB con­tin­ue to at­tract takeover in­ter­est. Most buy­ers these days, though, are look­ing to fol­low up on strate­gies adopt­ed by the likes of Al­ler­gan or Gilead. Al­ler­gan likes bit-sized deals – “step­ping stones,” if you ask CEO Brent Saun­ders — tar­get­ing late-stage as­sets that fit neat­ly in­to its core de­vel­op­ment ar­eas. Gilead has been stalk­ing li­cens­ing ef­forts that re­quire big up­front pay­ments. Ab­b­Vie $AB­BV may have set the stan­dard on over-ea­ger­ness when it paid $9.8 bil­lion for Stem­cen­trx in April. And Bio­gen ex­ecs have been talk­ing about deals for a sol­id year now.

But big game hunts have been sparse, more smoke than fire.

Val­u­a­tions, of course, are still well off the heights scaled a year ago, which may al­so help con­cen­trate ef­forts at the deal ta­ble. But they’re climb­ing, al­low­ing com­pa­nies like Bio­Marin (al­so reg­u­lar­ly fea­tured in the ru­mor mill) to raise more mon­ey. If sell­ers have more op­tions than tak­ing any­thing that’s put on the ta­ble, that can on­ly dri­ve deal val­ues fur­ther north.

For all the con­stant chat­ter about M&A, though, the re­al­i­ty is that plung­ing stocks have yet to trig­ger a much dis­cussed wave of ac­qui­si­tions.

Dealog­ic tracked $45 bil­lion in U.S. phar­ma and biotech M&A in the first half, a first-half low we haven’t seen since 2012, when the biotech boom was just start­ing to take off.

An­oth­er bit of food for thought: EP Van­tage just list­ed the most valu­able as­sets in the pipeline, based on sell-side analy­sis, top­ping it with Ax­o­vant’s $AX­ON late-stage drug for Alzheimer’s. In-li­censed from Glax­o­SmithK­line for $5 mil­lion in cash plus promis­es of more if it makes the grade, the bil­lions in val­ue at­trib­uted to such high-risk ef­forts un­der­scores that there may not be as many great deals avail­able as you might be­lieve.

UP­DAT­ED: Roche bags 'break­through' an­ti-fi­bro­sis drug in $1.4B biotech buy­out deal

Roche is snapping up a “breakthrough” anti-fibrotic drug in a $1.4 billion buyout.

The pharma giant announced Friday that it is acquiring Promedior, primarily to get its hands on PRM-151, a recombinant form of human pentraxin-2 (PTX-2) protein that has nailed down mid-stage clinical data on idiopathic pulmonary fibrosis and demonstrating its potential for a range of fibrotic conditions.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 65,600+ biopharma pros reading Endpoints daily — and it's free.

(Image: Associated Press)

Amarin emerges from an ex­pert pan­el re­view with a clear en­dorse­ment for Vas­cepa and high odds of suc­cess when the FDA weighs in for­mal­ly

Several FDA experts who gathered Thursday to consider the landmark approval of Vascepa to reduce cardio events in an at-risk population voiced their unease about various aspects of the efficacy and safety data, or ultimately the population it should be used to treat. But the overwhelming belief that the data pointed to the drug’s benefit and clearly outweighed risks carried the day for Amarin.

The panel voted unanimously (16 to 0) to support the company’s positive data presentation — backing an OK for expanding the label to include reducing cardio risk. The vote points Amarin $AMRN down a short path to a formal decision by the FDA, with the odds heavily in its favor. Chances are the rest of the questions about the future of this drug will be hashed out in the label’s small print.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 65,600+ biopharma pros reading Endpoints daily — and it's free.

No­var­tis spin­out’s first an­ti-ag­ing PhI­II is a flop, so now they’ll turn to Parkin­son’s chal­lenge as shares wilt

Novartis spinout resTORbio is grappling with the collapse of its lead clinical program this morning — an anti-aging R&D failure that will badly damage their rep in the field.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 65,600+ biopharma pros reading Endpoints daily — and it's free.

(Image: Associated Press)

No­var­tis scores its lat­est FDA OK — this time for a new sick­le cell dis­ease drug picked up in a $665M deal

Novartis’ decision to buy Oklahoma-based biotech Selexys 3 years ago for up to $665 million has paid off with an FDA approval today.

Blessed with the FDA’s breakthrough drug designation for a speedy review, the pharma giant has pinned down an approval for crizanlizumab, a new therapy designed to reduce the frequency of painful incidents of vaso-occlusive crises among sickle cell disease patients 16 or older.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 65,600+ biopharma pros reading Endpoints daily — and it's free.

As­traZeneca gains EU nod for di­a­betes triple; Am­gen and Duke launch re­al-world PC­SK9 ob­ser­va­tion­al study

→ Weeks after winning EU approval to start marketing dapagliflozin as Forxiga, AstraZeneca has racked up another OK for a triplet combo involving the SGLT2 diabetes drug. Named Qtrilmet, the pill combines Forxiga with the DPP-4 inhibitor Onglyza (saxagliptin) and the bedrock drug metformin in a modified-release format. That 3-in-1 approach proved superior in reducing average blood glucose levels to a number of other dual combinations across 5 Phase III trials, including Forxiga plus metformin, Onglyza with metformin, or glimepiride with metformin.

Five drugs, in­clud­ing two No­var­tis ther­a­pies, win EMA en­dorse­ment

As is custom, an EMA panel on Friday issued its weekly recommendations on marketing applications submitted by drug developers. This week, the agency backed the use of five new therapies — including two Novartis drugs — but issued no negative reviews.

Novartis’ S1P drug for relapsing forms of multiple sclerosis (MS) drug, Mayzent (known chemically as siponimod), which was approved by the FDA in March — has been given the nod by the EMA. The Swiss drugmaker already sells its other MS drug, Gilenya, in both regions.

Atom­wise's X-37 spin­out gets $14.5 mil­lion to launch AI dis­cov­ery ef­forts

The folks behind Atomwise’s spinout X-37 like to think in cosmological metaphors, and you can think of their AI drug development model as probes sent into space from a central station. That station just got $14.5 million in Series A funding from DCVC Bio, Alpha Intelligence Capital and Hemi Ventures to back those missions.

X-37 uses Atomwise’s AI platform to identify drug targets and – unlike the parent company, which largely sticks to computers  – bring those into a wet lab and preclinical testing.  In addition to AI professionals, it’s led in by part by drug developers from Velocity Pharmaceutical Development.

Ab­bott Lab­o­ra­to­ries CEO Miles White pass­es ba­ton down to suc­ces­sor; Lon­za CEO Marc Funk hits the ex­it

→ Abbott Laboratories has named a successor to CEO Miles White after he announced that he was stepping down in March after 21 years of service. Robert Ford, the company’s COO and president, will take the helm. Ford is known for his work in the $25 billion merger between St. Jude Medical into Abbott in January 2017. White will remain with the company as executive chairman of the board. 

→ After snapping up Novartis’ Swiss facility, Novartis Center of Excellence, in July, Lonza has announced that their CEO, Marc Funk, is hitting the exit for “personal reasons.” Funk has been the CEO of the company for less than a year — brought onto the company back in March. In the meantime, chairman Albert Baehny will serve as interim CEO. 

UCB adds on more pos­i­tive PhI­II da­ta for IL-17A/17F in­hibitor bimek­izum­ab, clear­ing a path to the FDA

A month after posting positive top-line data from their first Phase III trial of the IL-17A/17F inhibitor bimekizumab, Belgium’s UCB says they’ve added more upbeat results from their second late-stage test in moderate-to-severe plaque psoriasis.

That leaves the company on track for regulatory submissions in the middle of next year, says CMO Iris Loew-Friedrich.
Their drug beat out a placebo on the co-primaries — a 90% improvement in PASI 90 (the Psoriasis Area and Severity Index) and Investigator Global Assessment (IGA) response of clear or almost clear (IGA 0/1) at week 16, compared to placebo. Investigators also boasted of hitting some key secondaries.
UCB is angling to enter an increasingly crowded market space.
In their first of 3 Phase III studies for bimekizumab, researchers touted top-line wins on statistically significant results on clearing plaque psoriasis, including a victory over J&J’s IL-23 contender Stelara on key endpoints. The drug targets both IL-17A and IL-17F, a modification on the IL-17A strategy laid out for Taltz (Eli Lilly) and Cosentyx (Novartis). And the new group also includes J&J’s Tremfya and AbbVie’s Skyrizi.

Social image: UCB